During the past few years significant progress has been made in the treatment of cutaneous melanoma. These developments often involve the use of interferon-α (IFNα). Promising results have been reported in high risk patients using adjuvant treatment with high dose IFNα. A confirmatory trial of high dose IFNα and several adjuvant trials using low or intermediate dose IFNα are ongoing, and currently a standard regimen cannot be defined. High response rates have been reported in patients with metastatic disease with combination chemoimmunotherapy schedules. Randomized trials have to be performed in order to demonstrate a survival benefit over less toxic regimens. In this paper the current status of IFNα in the treatment of cutaneous melanoma is reviewed.